Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Monday 13 September, 2004

XTL Biopharm Ltd

AGM Statement

XTL Biopharmaceuticals Ltd
13 September 2004


XTL Biopharmaceuticals Ltd

AGM STATEMENT

Rehovot, Israel, 13 September 2004 - XTL Biopharmaceuticals Ltd ('XTLbio' or
'the Company'), the Israel-based biopharmaceutical company developing drugs
targeting hepatitis, announces that at its Annual General Meeting ('AGM') held
today at 12 noon, all resolutions proposed at the AGM were approved other than
resolution 2 giving authority to dis-apply pre-emption rights of up to 10% of
the Company's existing issued share capital. Whilst a majority of shareholders
voted in favour of this resolution, it did not obtain the necessary 75% approval
required by the Company's Articles of Association.

As suggested in resolutions 5-8, XTLbio will be adopting a more US and Israeli
Board structure with only one Executive member of the Board, Dr Martin Becker,
CEO, and five Non-Executive Directors, Dr Geoffrey Vernon, Dr Elkan Gamzu, Mr
Rusi Kathoke, Dr Patricia Smith, and Mr Peter Stalker. Dr Ehud Geller, a
non-executive director of XTLbio since 1996, has decided to step down from the
Board due to his other commitments relating to the management of the Medica
Ventures Fund. Three XTLbio executives, Mr Jonathan Burgin, Dr Shlomo Dagan and
Mr Glenn Kazo, did not seek re-election to the Board in order to allow XTLbio to
adopt the US and Israeli Board structure. These Board changes are effective
immediately.

Commenting after the AGM Dr. Geoffrey Vernon, Chairman of XTLbio, said:

'We are grateful to shareholders for their continuing support in a year in which
XTLbio has made significant achievements. Following our recent successful
fund-raising in July, XTLbio is in a strong cash position with investment from a
number of new top tier institutional investors from the UK, US and Israel. This
stands us in good stead to continue development of our key lead programs and to
develop our strategy for accessing the US capital markets.'

'I would also like to thank Dr Ehud Geller for his considerable contributions to
our Board over the past 8 years and those of our executives who have stepped
down from the Board.'

For further information please contact:

XTLbio
Dr. Martin Becker, President and CEO             Tel: +972 8 930 4440
Jonathan Burgin, Chief Financial Officer

Financial Dynamics
Julia Phillips, James Strong                     Tel: +44 (0) 20 7831 3113




                      This information is provided by RNS
            The company news service from the London Stock Exchange